Cough, cold and allergy (hay fever) remedies in Brazil is set to maintain solid retail current value growth in 2024, but with a growth rate below the overall OTC level, causing the category to lose some of its representation, falling by nearly a percentage point to a 33% share in OTC products. The poorest performances are anticipated for oral decongestants and nasal decongestant plasters, which are set to see declining retail value sales. One of the largest categories, cough remedies, is also ex

In 2024, cough, cold and allergy (hay fever) remedies is set to see continued moderate retail current value growth in India. With sales of antihistamines/allergy remedies insignificant, cough and cold remedies are expected to account for the entirety of sales. Growth in 2024 has primarily been fuelled by consumers’ increasing preference for herbal/traditional remedies. With rising awareness of the benefits of natural ingredients, a significant proportion of Indian consumers are prioritising herb

The pandemic led to a significant surge in sales of cough, cold, and allergy (hay fever) remedies in Singapore, particularly in 2022, as later COVID-19 variants exhibited symptoms similar to the common cold. However, in 2023 and 2024, with the country transitioning into the post-COVID-19 era, the overall growth rate of these remedies slowed considerably. Despite this, consumers remain proactive in managing their health at the first signs of illness, especially as they resume their social lives a

After the extreme uplift in sales caused by the COVID-19 pandemic, cough, cold and allergy remedies recorded a low level of growth in 2024. However, moderate growth remained, with antihistamines achieving decent value sales growth due to the frequency and intensity of allergies – especially seasonal allergies – rising. With few consumers wearing masks and social distancing becoming a less practised issue, infection rates for respiratory illnesses keep rising, albeit on a much more moderate level

Sales of cough, cold and allergy (hay fever) remedies in Germany continue to grow in 2024. While shortages of certain medicines and inflationary pressures from previous years continue to affect consumer behaviour, Germany is gradually returning to more typical patterns as respiratory infections drive demand. However, the spread of seasonal colds and flu at the beginning of the year was less severe than in 2023.

The growing market for cough, cold, and allergy remedies in Indonesia is closely linked to the phenomenon known as "pancaroba", which refers to the transitional period between the dry and rainy seasons. During this time, characterised by unpredictable weather patterns, residents experience a mix of hot, dry days followed by sudden rain showers. This transition typically occurs twice a year, around April-May and October-November, depending on the region.

Cough, cold and allergy (hay fever) remedies in Romania will see continued growth in current value terms in 2024. This performance is being driven by a higher incidence of viral infections and respiratory issues, prompting Romanians to seek faster treatments for their symptoms. Before the COVID-19 crisis, the category had reached a certain level of maturity but nevertheless experienced significant fluctuations in performance both during and after the pandemic. In 2020, for example, social distan

Cough, cold and allergy (hay fever) remedies is another consumer health category which remains popular in Cameroon in 2024. Indeed, there is a disturbing rise in coughs and colds in the country, also with seasonal allergies becoming more notable and lasting longer than seen in previous years. This has been attributed to the significant increase in air pollution, especially in major urban cities like Douala, Yaoundé, and Bafoussam, and also significant weather changes such as harsher weather duri

Total current value sales growth for cough, cold and allergy (hay fever) remedies in North Macedonia in 2024 looks set to be down on 2023. This is partly because pricing pressures are easing as inflation steadily recedes, but also reflects the fact that the winter season of 2023/2024 was relatively short and mild, which limited the need for some product types during the early months of the year. Nonetheless, all categories are still poised to post reasonably healthy growth in volume terms. Along

There is expected to be muted constant value growth for cough, cold and allergy (hay fever) remedies in Poland in 2024, with volume growth muted or negative across most product areas. The flu season is not expected to be as bad as in 2023 and this is expected to dampen volume sales.

Climate change is directly impacting the cough, cold and allergy (hay fever) category in Tunisia. Compared to previous decades, Tunisia is witnessing notable changes to its climate, with hotter temperatures and shorter winters taking effect. By consequence, there has been a remarkable decrease in cases of winter illnesses like colds and flu. Traditionally, cold and flu viruses would boost sales for 4-6 months each year in Tunisia. Consequently, there has been a decline in demand for cough and co

The market for cough, cold, and allergy remedies in Switzerland is anticipated to continue its growth trajectory in 2024, fuelled by erratic weather patterns and a return to normal lifestyles following the pandemic. Cough remedies are expected to be the primary growth driver, as the transmission of viruses and flu frequently results in coughing that requires relief. While air quality across Europe has seen improvements, air pollution remains a significant health concern, contributing to respirat

Cough, cold and allergy (hay fever) remedies is the biggest category in OTC in Ukraine with the most popular products being decongestants, pharyngeal preparations and combination products – cough, cold and allergy (hay fever) remedies. In many countries there was an uptick in demand for cough, cold and allergy (hay fever) remedies in 2022 as fears around COVID-19 softened and restrictions were lifted, with consumers socialising more and thus increasing the spread of viruses such as cold and flu.

In spite of continuing high inflation, cough, cold and allergy (hay fever remedies) is expected to register healthy constant value growth in Pakistan in 2024. A high incidence of respiratory illnesses is driving growth and this is partly due to rising pollution. Combination products continue to account for most value sales, though in 2024, medicated confectionery is expected to register the highest value growth. Consumers appreciate the convenience and pleasant taste of medicate confectionery an

Value sales of cough, cold and allergy (hay fever) remedies in South Africa continue to rise across the category in 2024, although overall demand is mainly driven by combination products, cough remedies, decongestants, medicated confectionery and pharyngeal preparations. Albeit from a low base, decongestant rubs is recording particularly dynamic retail volume growth.

Cough, cold and allergy (hay fever) remedies remained the largest product area within consumer health in Sweden in 2024. Consumer demand continues to normalise after the highs of the pandemic, but there are diverging results depending on the category. Combination products, cough remedies and decongestants are all showing signs of normalisation. Medicated confectionery sales continue to decline as Swedes turn to more effective remedies for a sore throat. One of the best performers was antihistami

As COVID-19 restrictions have eased in Uzbekistan, the cough, cold and allergy remedy landscape was poised for a recovery. However, the introduction of restrictions and regulations for new and existing players has led to significant challenges. Due to the death of children and young people who consumed contaminated cough syrups from Indian brands, new government regulations required mandatory marking. In contrast, international brands have aligned with a new registration process while repeating

Manufacturers have raised their prices, leading to double-digit retail value growth on the landscape. Nonetheless, in many cases, consumers have continued to buy expensive branded options, having more confidence in items they are familiar with. Consequently, over 2024, all significant product areas will continue to record positive retail volume growth despite heightened prices. This mirrors the development of cough, cold and allergy (hay fever) remedies, with wide fluctuations in growth trajecto

The weaker value growth seen in cough and cold, allergy (hay fever) remedies in 2024 can be attributed to falling inflation in Serbia and the lower incidence of coughs and colds at the beginning of 2024. Unit prices continued to rise in line with the arrival of several new launches in 2023-24. The leading brand Prospan has launched a new syrup flavour adapted specifically for adults. Fenistil also launched new packaging of its gel product.

Responsible conduct during the pandemic, such as wearing face masks, practising social distancing, and frequently washing hands, effectively limited the spread of flu-like viruses and reduced the number of people affected by commonly transmitted coughs and colds. With the full reopening of society and return to schools and workplaces, the number of cough and cold cases are back to pre-pandemic levels in 2024 and volume sales of cough and cold remedies are consequently recording solid growth. Sig

The market for cough, cold, and allergy remedies in Taiwan is expected to grow in current value terms in 2024, driven by a rise in respiratory infections, compounded by the country’s high asthma prevalence. Environmental pollution is a key factor exacerbating asthma, with approximately two million Taiwanese affected, many of whom are unaware of their condition. Chronic cough, a key asthma symptom, becomes more common with fluctuating temperatures, increasing the risk of attacks, particularly in

The widespread availability and affordability of OTC cough, cold and allergy (hay fever) medications in Kenya have made them a popular choice for managing minor respiratory symptoms. Rising pollution levels has been driving sales in 2024, with both indoor and outdoor air pollution causing respiratory issues. Consumers benefit from the convenience of purchasing these medications without a prescription, which has encouraged many local brands to enter the category. As awareness grows about the effe

The market for cough, cold, and allergy remedies in Slovakia is projected to maintain healthy growth in current value terms in 2024. While shortages of certain medicines and inflationary pressures of p[previous years will continue to have a lingering effect on consumer behaviour, the market is gradually returning to more typical patterns as respiratory infections drive demand. However, the spread of seasonal colds and flu appears to be less severe compared to 2023, which may slightly temper grow

Cough, cold and allergy (hay fever) remedies is expected to see strong current value growth in Israel in 2024. The paediatric cough, cold and allergy (hay fever) remedies category is set to register good volume growth over 2024 as parents continue to buy products for their children to help relieve discomfort. A hot, dry and dusty climate, coupled with destruction and damage to the ground and buildings from rockets used in the Israel-Hamas war, means that there is a lot of dust around in 2024, wh